Newer compounds like retatrutide add a third receptor target (GIP, GLP-1, and glucagon) and may create unique nutritional challenges that have not yet been well-studied
The Fine Print on the Medicare GLP-1 Bridge A few things to know before you plan around this: The $50 doesnt count toward your Part D out-of-pocket max
The slowdown came fast, steadily, and relentlessly, as seen in Intuitives subsequent quarterly commentary: Q323: In bariatrics, we continued to see double digit growth albeit at a modestly lower growth rate compared to Q2 Q423: We saw a continued deceleration in growth throughout 2023, likely the result of the uptake of GLP-1 drugs. Q124: Bariatric procedure growth continued to moderate and was flat year-over-year
When GLP-1 medications have slowed everything down, targeted movement can help restart the engine
Immunity 55 , 3155 (2022)